Alveolar epithelial and endothelial cell apoptosis in emphysema: What we know and what we need to know

International Journal of COPD

Volumn 4, Issue 1, 2009, Pages 19-31

  Morissette, Mathieu C ^a   Parent, Julie ^a   Milot, Julie ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b NONE   (Canada)

Author keywords

Apoptosis; Autoimmunity; Emphysema; Oxidative stress; Proteases; TRAIL; VEGF

Indexed keywords

ALPHA 1 ANTITRYPSIN; ELASTASE; PROTEINASE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN;

APOPTOSIS; AUTOIMMUNITY; CELL DEATH; CELL TYPE; CIGARETTE SMOKING; DNA FRAGMENTATION; EMPHYSEMA; ENZYME ACTIVITY; HUMAN; KILLER CELL; LUNG ALVEOLUS EPITHELIUM; LUNG ENDOTHELIUM; NONHUMAN; OXIDATIVE STRESS; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; AUTOIMMUNITY; ENDOTHELIAL CELLS; HUMANS; OXIDATIVE STRESS; PEPTIDE HYDROLASES; PULMONARY ALVEOLI; PULMONARY EMPHYSEMA; RESPIRATORY MUCOSA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 66149097817     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-1504.
2. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364:709-721.
3. Mulgrew AT, Taggart CC, McElvaney NG. Alpha-1-antitrypsin deficiency: current concepts. Lung. 2007;185:191-201.
4. Quint JK, Wedzicha JA. The neutrophil in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2007;119:1065-1071.
5. Barnes PJ. Alveolar macrophages in chronic obstructive pulmonary disease (COPD). Cell Mol Biol (Noisy-le-grand). 2004;50: OL627-OL637.
6. Cosio MG, Majo J, Cosio MG. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest. 2002;121:160S-165S.
7. Strasser A, O'Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem. 2000;69:217-245.
8. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006;12:440-450.
9. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495-516.
10. Imai K, Mercer BA, Schulman LL, et al. Correlation of lung surface area to apoptosis and proliferation in human emphysema. Eur Respir J. 2005;25:250-258.
11. Yokohori N, Aoshiba K, Nagai A. Increased levels of cell death and proliferation in alveolar wall cells in patients with pulmonary emphysema. Chest. 2004;125:626-632.
12. Yang JJ, Kettritz R, Falk RJ, et al. Apoptosis of endothelial cells induced by the neutrophil serine proteases proteinase 3 and elastase. Am J Pathol. 1996;149:1617-1626.
13. Ginzberg HH, Shannon PT, Suzuki T, et al. Leukocyte elastase induces epithelial apoptosis: role of mitochondial permeability changes and Akt. Am J Physiol Gastrointest Liver Physiol. 2004;287:G286-G298.
14. Suzuki T, Moraes TJ, Vachon E, et al. Proteinase-activated receptor-1 mediates elastase-induced apoptosis of human lung epithelial cells. Am J Respir Cell Mol Biol. 2005;33:231-247.
15. Petrache I, Fijalkowska I, Medler TR, et al. alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol. 2006;169:1155-1166.
16. Aldonyte R, Hutchinson ET, Jin B, et al. Endothelial alpha-1-antitrypsin attenuates cigarette smoke induced apoptosis in vitro. COPD. 2008;5:153-162.
17. Chirco R, Liu XW, Jung KK, et al. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006;25:99-113.
18. Eriksson S. Pulmonary emphysema and alpha1-antitrypsin deficiency. Acta Med Scand. 1964;175:197-205.
19. Gross P, Pfitzer EA, Tolker E, et al. Experimental emphysema: its production with papain in normal and silicotic rats. Arch Environ Health. 1965;11:50-58.
20. Yoshioka A, Betsuyaku T, Nishimura M, et al. Excessive neutrophil elastase in bronchoalveolar lavage fluid in subclinical emphysema. Am J Respir Crit Care Med. 1995;152:2127-2132.
21. Takeyabu K, Betsuyaku T, Nishimura M, et al. Cysteine proteinases and cystatin C in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Eur Respir J. 1998;12:1033-1039.
22. Segura-Valdez L, Pardo A, Gaxiola M, et al. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest. 2000;117:684-694.
23. Imai K, Dalal SS, Chen ES, et al. Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am J Respir Crit Care Med. 2001;163:786-791.
24. Ohnishi K, Takagi M, Kurokawa Y, et al. Matrix metalloproteinasemediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest. 1998;78:1077-1087.
25. Babusyte A, Stravinskaite K, Jeroch J, et al. Patterns of airway inflammation and MMP-12 expression in smokers and ex-smokers with COPD. Respir Res. 2007;8:81.
26. Stone PJ, Lucey EC, Calore JD, et al. Defenses of the hamster lung against human neutrophil and porcine pancreatic elastase. Respiration. 1988;54:1-15.
27. Lucey EC, Keane J, Kuang PP, et al. Severity of elastase-induced emphysema is decreased in tumor necrosis factor-alpha and interleukin-1-beta receptor-deficient mice. Lab Invest. 2002;82:79-85.
28. Zheng T, Kang MJ, Crothers K, et al. Role of cathepsin S-dependent epithelial cell apoptosis in IFN-gamma-induced alveolar remodeling and pulmonary emphysema. J Immunol. 2005;174:8106-8115.
29. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
30. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem. 1998;273:13313-13316.
31. Gupta K, Kshirsagar S, Li W, et al. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res. 1999;247:495-504.
32. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 1998;273:30336-30343.
33. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998; 282:1318-1321.
34. del Peso L, Gonzalez-Garcia M, Page C, et al. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997;278:687-689.
35. Tran J, Rak J, Sheehan C, et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun. 1999;264:781-788.
36. Kanazawa H. Role of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Med Sci Monit. 2007;13:RA189-195.
37. Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol. 2006;290: L209-L221.
38. Marwick JA, Stevenson CS, Giddings J, et al. Cigarette smoke disrupts VEGF165-VEGFR-2 receptor signaling complex in rat lungs and patients with COPD: morphological impact of VEGFR-2 inhibition. Am J Physiol Lung Cell Mol Physiol. 2006;290:L897-908.
39. Kasahara Y, Tuder RM, Cool CD, et al. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med. 2001;163:737-744.
40. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000;106:1311-1319.
41. Tuder RM, Zhen L, Cho CY, et al. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol. 2003;29:88-97.
42. Demura Y, Taraseviciene-Stewart L, Scerbavicius R, et al. N-acetylcysteine treatment protects against VEGF-receptor blockade-related emphysema. COPD. 2004;1:25-32.
43. Committee ahS. Mechanisms and limits of induced postnatal lung growth. Am J Respir Crit Care Med. 2004;170:319-343.
44. Acarregui MJ, Penisten ST, Goss KL, et al. Vascular endothelial growth factor gene expression in human fetal lung in vitro. Am J Respir Cell Mol Biol. 1999;20:14-23.
45. Shifren JL, Doldi N, Ferrara N, et al. In the human fetus, vascular endothelial growth factor is expressed in epithelial cells and myocytes, but not vascular endothelium: implications for mode of action. J Clin Endocrinol Metab. 1994;79:316-322.
46. Ng YS, Rohan R, Sunday ME, et al. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn. 2001;220:112-121.
47. Ryter SW, Kim HP, Hoetzel A, et al. Mechanisms of cell death in oxidative stress. Antioxid Redox Signal. 2007;9:49-89.
48. Jing Y, Dai J, Chalmers-Redman RM, et al. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood. 1999;94:2102-2111.
49. Serrano J, Palmeira CM, Kuehl DW, et al. Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim Biophys Acta. 1999;1411:201-205.
50. Hug H, Strand S, Grambihler A, et al. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J Biol Chem. 1997;272:28191-28193.
51. Suzuki S, Higuchi M, Proske RJ, et al. Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. Oncogene. 1999;18:6380-6387.
52. Carvalho H, Evelson P, Sigaud S, et al. Mitogen-activated protein kinases modulate H(2)O(2)-induced apoptosis in primary rat alveolar epithelial cells. J Cell Biochem. 2004;92:502-513.
53. Rahman I, Biswas SK, Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol. 2006;533:222-239.
54. Pryor WA. Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Environ Health Perspect. 1997;105 (Suppl 4):875-882.
55. Willemse BW, Postma DS, Timens W, et al. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J. 2004;23:464-476.
56. Russell RE, Culpitt SV, DeMatos C, et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2002;26:602-609.
57. Russell RE, Thorley A, Culpitt SV, et al. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol. 2002;283:L867-73.
58. Lacoste JY, Bousquet J, Chanez P, et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 1993;92:537-548.
59. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med. 1997;155:449-453.
60. Gwinn MR, Vallyathan V. Respiratory burst: role in signal transduction in alveolar macrophages. J Toxicol Environ Health B Crit Rev. 2006;9:27-39.
61. Dahlgren C, Karlsson A. Respiratory burst in human neutrophils. J Immunol Methods. 1999;232:3-14.
62. Rahman I, van Schadewijk AA, Crowther AJ, et al. 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:490-495.
63. Malhotra D, Thimmulappa R, Navas-Acien A, et al. Decline in NRF2 Regulated Antioxidants in COPD Lungs due to Loss of its Positive Regulator DJ-1. Am J Respir Crit Care Med. 2008.
64. Falschlehner C, Emmerich CH, Gerlach B, et al. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol. 2007;39:1462-1475.
65. Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics. Int J Oncol. 1999;15:793-802.
66. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2005;12:228-237.
67. Hu H, Jiang C, Schuster T, et al. Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/ Baxmediated activation of mitochondrial pathway. Mol Cancer Ther. 2006;5:1873-1882.
68. Fan QL, Zou WY, Song LH, et al. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo. Cancer Chemother Pharmacol. 2005;55:189-196.
69. Frese S, Brunner T, Gugger M, et al. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein. J Thorac Cardiovasc Surg. 2002;123:168-174.
70. Uberti D, Ferrari-Toninelli G, Bonini SA, et al. Blockade of the tumor necrosis factor-related apoptosis inducing ligand death receptor DR5 prevents beta-amyloid neurotoxicity. Neuropsychopharmacology. 2007;32:872-880.
71. Robertson NM, Zangrilli JG, Steplewski A, et al. Differential expression of TRAIL and TRAIL receptors in allergic asthmatics following segmental antigen challenge: evidence for a role of TRAIL in eosinophil survival. J Immunol. 2002;169:5986-5996.
72. Robertson NM, Rosemiller M, Lindemeyer RG, et al. TRAIL in the airways. Vitam Horm. 2004;67:149-167.
73. Mirandola P, Ponti C, Gobbi G, et al. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood. 2004;104:2418-2424.
74. Morissette MC, Vachon-Beaudoin G, Parent J, et al. Increased p53 level, Bax/Bcl-x(L) ratio, and TRAIL receptor expression in human emphysema. Am J Respir Crit Care Med. 2008;178:240-247.
75. Andersen MH, Schrama D, Thor Straten P, et al. Cytotoxic T cells. J Invest Dermatol. 2006;126:32-41.
76. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 2006;20:123-137.
77. Atassi MZ, Casali P. Molecular mechanisms of autoimmunity. Autoimmunity. 2008;41:123-132.
78. Gaipl US, Kuhn A, Sheriff A, et al. Clearance of apoptotic cells in human SLE. Curr Dir Autoimmun. 2006;9:173-187.
79. Scofield RH. Autoantibodies as predictors of disease. Lancet. 2004;363:1544-1546.
80. Gao H, Neff T, Ward PA. Regulation of lung inflammation in the model of IgG immune-complex injury. Annu Rev Pathol. 2006;1:215-242.
81. Smyth MJ, Cretney E, Kelly JM, et al. Activation of NK cell cytotoxicity. Mol Immunol. 2005;42:501-510.
82. Elson CJ, Barker RN. Helper T cells in antibody-mediated, organspecific autoimmunity. Curr Opin Immunol. 2000;12:664-669.
83. Walter U, Santamaria P. CD8+ T cells in autoimmunity. Curr Opin Immunol. 2005;17:624-631.
84. Feghali-Bostwick CA, Gadgil AS, Otterbein LE, et al. Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:156-163.
85. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, et al. An animal model of autoimmune emphysema. Am J Respir Crit Care Med. 2005;171:734-742.
86. Lee SH, Goswami S, Grudo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med. 2007;13:567-569.
87. Sullivan AK, Simonian PL, Falta MT, et al. Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema. Am J Respir Crit Care Med. 2005;172:590-596.
88. Sullivan AK, Simonian PL, Falta MT, et al. Activated oligoclonal CD4+ T cells in the lungs of patients with severe emphysema. Proc Am Thorac Soc. 2006;3:486.
89. Korn S, Wiewrodt R, Walz YC, et al. Characterization of the interstitial lung and peripheral blood T cell receptor repertoire in cigarette smokers. Am J Respir Cell Mol Biol. 2005;32:142-148.
90. Chrysofakis G, Tzanakis N, Kyriakoy D, et al. Perforin expression and cytotoxic activity of sputum CD8+ lymphocytes in patients with COPD. Chest. 2004;125:71-76.
91. Hodge S, Hodge G, Nairn J, et al. Increased airway granzyme b and perforin in current and ex-smoking COPD subjects. COPD. 2006;3:179-187.
92. Morissette MC, Parent J, Milot J. Perforin, granzyme B, and FasL expression by peripheral blood T lymphocytes in emphysema. Respir Res. 2007;8:62.
93. Liu CY, Lin HC, Yu CT, et al. The concentration-dependent chemokine release and pro-apoptotic effects of neutrophil-derived alpha-defensin-1 on human bronchial and alveolar epithelial cells. Life Sci. 2007;80:749-758.
94. Aarbiou J, Tjabringa GS, Verhoosel RM, et al. Mechanisms of cell death induced by the neutrophil antimicrobial peptides alpha-defensins and LL-37. Inflamm Res. 2006;55:119-127.
95. Taraseviciene-Stewart L, Voelkel NF. Molecular pathogenesis of emphysema. J Clin Invest. 2008;118:394-402.
96. Vandivier RW, Henson PM, Douglas IS. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest. 2006;129:1673-1682.
97. Calabrese F, Giacometti C, Beghe B, et al. Marked alveolar apoptosis/ proliferation imbalance in end-stage emphysema. Respir Res. 2005;6:14.
98. Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol. 2003;28:555-562.
99. Bartalesi B, Cavarra E, Fineschi S, et al. Different lung responses to cigarette smoke in two strains of mice sensitive to oxidants. Eur Respir J. 2005;25:15-22.
100. Kuo WH, Chen JH, Lin HH, et al. Induction of apoptosis in the lung tissue from rats exposed to cigarette smoke involves p38/JNK MAPK pathway. Chem Biol Interact. 2005;155:31-42.
101. Petrache I, Natarajan V, Zhen L, et al. Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med. 2005;11:491-498.
102. Brass DM, Hollingsworth JW, Cinque M, et al. Chronic LPS Inhalation Causes Emphysema-like Changes in Mouse Lung that is Associated with Apoptosis. Am J Respir Cell Mol Biol. 2008.